This Plain Language Summary of Publication article (PLSP) from Future Oncology examined nadofaragene firadenovec (Adstiladrin), a gene therapy for non-muscle-invasive bladder cancer patients unresponsive to standard BCG treatment. The therapy works by introducing a non-replicating virus into the bladder that delivers a gene enabling the body to produce interferon alfa-2b, a cancer-fighting protein. Conducted across multiple US medical centers with a 5-year follow-up design, researchers monitored participants’ health for an average of over 3 years after treatment initiation to evaluate the therapy’s safety and effectiveness.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial’ and was published in the Lancet Oncology.

Visit The Lancet using the link to read the original article.